Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Neutral 74.0%

Neg 0% Neu 74% Pos 0%

Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.